Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)

被引：1

作者：

Morgans, A. K. ^{[1
]}

Gschwend, J. E. ^{[2
]}

Shore, N. D. ^{[3
]}

Ross, A. ^{[4
]}

Feng, F. ^{[5
]}

Hope, T. ^{[6
]}

Trandafir, L. ^{[7
]}

Le Berre, M-A. ^{[8
]}

Kuss, I. ^{[9
]}

Joensuu, H. ^{[10
]}

Fizazi, K. ^{[11
]}

机构：

[1] Dana Farber Canc Inst, Med Dept, Boston, MA USA

[2] Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, Munich, Germany

[3] GenesisCare US, Uro Oncol Dept, Carolina Urol Res Ctr, Myrtle Beach, SC USA

[4] Northwestern Univ, Urol, Feinberg Sch Med, Chicago, IL USA

[5] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Radiat Oncol, San Francisco, CA USA

[6] Univ Calif San Francisco, Radiol Sch Med, San Francisco, CA USA

[7] Bayer Consumer Care AG, R&D Dept, Basel, Switzerland

[8] Bayer Healthcare France, Biometry, Loos, France

[9] Bayer AG, Clin Dev SBU Oncol, Berlin, Germany

[10] Orion Corp, Orion Pharma, Espoo, Finland

[11] Univ Paris Saclay, Dept Canc Med, Gustave Roussy, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2789

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

184TiP

引用

页码：S997 / S998

页数：2

共 50 条

[1] Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
Chehrazi-Raffle, Alex
Morgans, Alicia K.
Gschwend, Jurgen E.
Shore, Neal D.
Ross, Ashley
Feng, Felix Y.
Hope, Thomas A.
Trandafir, Lucia
Kuss, Iris
Le Berre, Marie-Aude
Joensuu, Heikki
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS254 - TPS254
[2] Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
Morgans, Alicia K.
Niazi, Tamim
Shore, Neal D.
Gschwend, Juergen E.
Ross, Ashley
Hope, Thomas A.
Chehrazi-Raffle, Alex
Supiot, Stephane
Barthelemy, Philippe
Roder, Andreas
Gomes, Andrea Juliana
Imbroda, Bernardo Herrera
Gratton, Matthieu
Ruiz, Carmen Belen Congregado
Joensuu, Heikki
Dimova-Dobreva, Miryana
Le Berre, Marie-Aude
Kuss, Iris
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS432 - TPS432
[3] Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP)
Chehrazi-Raffle, Alex
Morgans, Alicia K.
Gschwed, Jurgen E.
Shore, Neal D.
Ross, Ashley
Feng, Felix Y.
Hope, Thomas A.
Nordquist, Luke
Niazi, Tamim
Trandafir, Lucia
Le Berre, Marie-Aude
Kuss, Iris
Joensuu, Heikki
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)
Taplin, Mary-Ellen
Gleave, Martin
Evans, Christopher P.
Efstathiou, Eleni
Kantoff, Philip W.
Ross, Ashley
Shore, Neal D.
Briganti, Alberto
Hadaschik, Boris A.
Heidenreich, Axel
Rooney, Oliver Brendan
Tian, Shaozhou Ken
Wetherhold, Lisa
Xu, Weichun
Cheng, Shinta
Brookman-May, Sabine Doris
Lopez-Gitlitz, Angela
Kibel, Adam S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[5] DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.
Niazi, Tamim
Williams, Scott
Davis, Ian D.
Stockler, Martin R.
Martin, Andrew James
Bracken, Karen
Roncolato, Felicia
Horvath, Lisa
Martin, Jarad
Lim, Tee Sin
Hughes, Simon
McDermott, Raymond S.
Catto, James W. F.
Kelly, Paul J.
McBride, Sean Matthew
Parulekar, Wendy R.
Morgan, Scott Carlyle
Rendon, Ricardo A.
Sweeney, Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[6] DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer
Niazi, Tamim
Williams, Scott
Davis, Ian D.
Stockler, Martin R.
Martin, Andrew James
Hague, Wendy
Bracken, Karen
Gorzeman, Margot
Roncolato, Felicia
Yip, Sonia
Horvath, Lisa
Sengupta, Shomik
Hughes, Simon
McDermott, Raymond S.
Catto, James W. F.
Vapiwala, Neha
Parulekar, Wendy R.
Sweeney, Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[7] DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.
Niazi, Tamim
McBride, Sean Matthew
Williams, Scott
Davis, Ian D.
Stockler, Martin R.
Martin, Andrew James
Chung, Hans T.
Roncolato, Felicia
Ebacher, Annie
Khoo, Eric
Martin, Jarad
Lim, Tee Sin
Hughes, Simon
Pryor, David
Catto, James W. F.
Kelly, Paul
Rezaei, Leily Gholam
Morgan, Scott C.
Rendon, Ricardo A.
Sweeney, Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[8] DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
Niazi, T.
Williams, S.
Davis, I. D.
Stockler, M. R.
Martin, A.
Bracken, K.
Roncolato, F.
McJannett, M.
Horvath, L.
Sengupta, S.
Hughes, S.
McDermott, R.
Catto, J.
Kelly, P.
Vapiwala, N.
Parulekar, W. R.
Morgan, S.
Rendon, R. A.
Sweeney, C.
ANNALS OF ONCOLOGY, 2020, 31 : S548 - S549
[9] DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
Niazi, Tamim
McBride, Sean Matthew
Williams, Scott
Davis, Ian D.
Stockler, Martin R.
Martin, Andrew James
Bracken, Karen
Roncolato, Felicia
Horvath, Lisa
Sengupta, Shomik
Martin, Jarad
Lim, Tee
Hughes, Simon
McDermott, Raymond S.
Catto, James W. F.
Kelly, Paul J.
Parulekar, Wendy R.
Morgan, Scott Carlyle
Rendon, Ricardo A.
Sweeney, Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).
Taplin, Mary-Ellen
Gleave, Martin
Evans, Christopher P.
Efstathiou, Eleni
Kantoff, Philip W.
Ross, Ashley
Shore, Neal D.
Briganti, Alberto
Hadaschik, Boris A.
Heidenreich, Axel
Rooney, Oliver Brendan
Tian, Shaozhou Ken
Wetherhold, Lisa
Xu, Weichun
Cheng, Shinta
Kibel, Adam S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →